Similar to MEK inhibitors (above) and KRASG12C inhibitors (below), tipifarnib treatment of HRAS-mutated cancer cells show adaptive reactivation RTK–WT RAS signaling and enhanced RAF/MEK/ERK pathway activation [91]. Here, RAF1 is linked to cancer.